Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)

Publication date: Available online 14 November 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, L. Jeffrey Medeiros, Michael J. Overman, Jorge E. Romaguera, Loretta Nastoupil, Michael Wang, Fredrick B. Hagemeister, Alma Rodriguez, Yasuhiro Oki, Jason Westin, Francesco Turturro, Sattva S. Neelapu, Luis Fayad The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. This is a case series of 45 patients with FLG3 treated with frontline R-CHOP and observed for an extended time interval. The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years. The baseline characteristic more strongly associated with a shorter PFS were lymph node sites more than 4 and presence of B symptoms. Three patients later progressed to DLBCL, all had baseline elevated serum LDH and high IPI score. Median overall survival (OS) has not been reached. All 4 patients who later developed AML were older than 60 at the time of start of therapy. R-CHOP is an effective frontline treatment for patients with FLG3, and may provide extended PFS, comparable to outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research